Comparison of efficacy and safety of sitagliptin or ipragliflozin in type 2 diabetic patients with insulin therapy

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2014
INTERVENTION: Treatment with ipraglifrozin. Treatment with sitagliptin. CONDITION: Type 2 diabetes PRIMARY OUTCOME: HbA1c(non‐inferiority margin is 0.4%) INCLUSION CRITERIA: Patients who have HbA1c levels 7 or more %
Epistemonikos ID: d447e55645e8f14c49dded0c59ee6ce9c4def03d
First added on: Aug 23, 2024